Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ocular Therapeutix Inc | OCUL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.02 | 06:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.02 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.995 - 11.31 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 5.02 | USD |
Ocular Therapeutix Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 746.11M | 148.63M | - | 58.44M | -80.74M | -0.54 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ocular Therapeutix News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCUL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.44 | 5.43 | 4.06 | 4.66 | 3,482,448 | 0.58 | 13.06% |
| 1 Month | 8.62 | 8.94 | 4.06 | 5.76 | 2,840,437 | -3.60 | -41.76% |
| 3 Months | 5.02 | 11.31 | 4.06 | 7.89 | 2,671,385 | 0.00 | 0.00% |
| 6 Months | 3.19 | 11.31 | 1.995 | 6.39 | 1,973,827 | 1.83 | 57.37% |
| 1 Year | 6.15 | 11.31 | 1.995 | 5.86 | 1,469,396 | -1.13 | -18.37% |
| 3 Years | 18.35 | 18.6027 | 1.995 | 6.44 | 1,083,595 | -13.33 | -72.64% |
| 5 Years | 3.73 | 24.30 | 1.995 | 7.66 | 1,013,950 | 1.29 | 34.58% |
Ocular Therapeutix Description
| Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. |
